Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of CanProbe.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
CanProbe
Canada Flag
Country
Country
Canada
Address
Address
Toronto General Hospital, Toronto
Telephone
Telephone
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

POINT Biopharma has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium–177 Octreotate for the treatment of neuroendocrine cancer. Lu-DOTATATE as it is being used in 167 neuroendocrine tumor patients in a 180-patient trial.


Lead Product(s): Lutetium–177 Octreotate

Therapeutic Area: Oncology Product Name: Lu-DOTATATE

Highest Development Status: Phase IIIProduct Type: Peptide

Partner/Sponsor/Collaborator: Point Biopharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 12, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY